• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study shows fewer out-of-target blood glucose levels using Ascensia’s monitoring system

May 2, 2022 By Sean Whooley

Ascensia DiabetesAscensia Diabetes Care announced today that a new study demonstrates reduced out-of-target blood glucose ranges with its Contour system.

The company, which distributes Senseonics’ Eversense continuous glucose monitor (CGM), develops the Contour blood glucose monitoring (BGM) systems and the Contour diabetes app (CDA) for people with diabetes who are managing their blood glucose levels.

According to a news release, the new study — presented at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2022 in Barcelona — showed that people who used the connected Contour BGM systems and app for at least six months can see a reduced frequency of hypoglycemic and hyperglycemic blood glucose readings (BGRs). Ascensia said the data suggests the key benefit of using the systems to avoid out-of-target blood glucose ranges that can lead to serious health complications.

The study assessed data from 7,047 Contour system users in Australia. After six months, the estimated frequency of BGRs in high and very high ranges of people using the system fell by more than 6.5 times and 5.6 times, respectively, compared to baseline.

Ascensia said the decrease was more prominent among users who reported the use of oral antidiabetic medications. Decrease of BGRs in the low range was modest at 1.2 times in the entire study population and registered at 1.38 times in Contour users who were treated with insulin and are more prone to hypoglycemic events.

The majority of those assessed had type 2 diabetes (66.9%).

“We’re pleased to see results from the study showcasing that our CDA system is helping people with diabetes to manage their condition,” Ascensia Head of BGM Marketing and Strategy Frank Held said in the release. “While many diabetes apps support people with diabetes in managing their condition, they don’t all provide alerts or guidance for hypoglycaemic or hyperglycaemic events, like the Contour diabetes app does. Failure to properly address these events can result in serious health complications, so it is crucial that monitoring systems and connected apps facilitate the detection of high and low blood glucose levels.”

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Ascensia Diabetes Care

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS